Anzeige
Mehr »
Mittwoch, 18.06.2025 - Börsentäglich über 12.000 News
Entsteht hier die interessanteste spekulative Chance im kommenden Rohstoff-Boom?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 | ISIN: US1101221083 | Ticker-Symbol: BRM
Tradegate
18.06.25 | 19:12
40,730 Euro
-0,94 % -0,385
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
40,56040,64019:31
40,56540,70019:29

Aktuelle News zur BRISTOL-MYERS SQUIBB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBristol Myers Squibb declares quarterly dividend of $0.62 per share37
DiBristol-Myers Squibb Company declares $0.62 dividend10
MoBiogen leads Cannes Lions Pharma shortlist, with BMS, Novartis cracking Health & Wellness category30
FrBMS taps biotech analyst from Goldman Sachs to lead long-term strategy33
FrBMY Focuses on Label Expansion of Drugs: Will This Revive Growth?11
DoBristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum42
DoBMY Reports Positive Data on Sotyktu From Arthritis Study6
DoBristol-Myers stock holds steady as Cantor maintains neutral rating9
BRISTOL-MYERS SQUIBB Aktie jetzt für 0€ handeln
11.06.David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field12
11.06.Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer15
11.06.Bristol Myers bolsters radiopharma portfolio with PhiloChem deal7
11.06.Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio1
11.06.Bristol-Myers' RayzeBio signs a license deal with Philochem4
11.06.BMS' radiopharma unit builds with $1.35bn Philochem deal8
11.06.BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal5
11.06.Bristol-Myers Squibb to acquire rights to prostate cancer drug for $350m11
11.06.Philogen S.p.A.: Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.3463Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN...
► Artikel lesen
09.06.FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer39
08.06.Notable healthcare headlines for the week: Bristol Myers Squibb, Novo Nordisk and Sanofi in focus76
06.06.Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?31
Weiter >>
435 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,10